文献速递肾小球疾病

抗PLA2R抗体水平与膜性肾病治疗无反应的临床风险因素

Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-07-20

该研究基于MENTOR试验中85例抗PLA2R抗体≥14 RU/ml的膜性肾病患者,识别环孢素或利妥昔单抗治疗12个月后未达蛋白尿缓解的风险因素。发现治疗3个月时结合抗体与白蛋白水平变化的模型预测性能最佳,显著优于基线模型,而6个月模型较3个月无额外获益。

要点

  • 基线最佳预测无缓解模型包括抗PLA2R抗体>323 RU/ml和肌酐清除率。
  • 治疗3个月最佳模型包括抗体和 Alb 相对基线的变化。
  • 3个月模型拟合优度与C-statistic均优于基线模型。

核心结论

  • 在MENTOR试验中接受环孢素或利妥昔单抗治疗的膜性肾病患者,评估治疗反应概率风险因素的最佳方法是使用治疗3个月后的抗PLA2R抗体水平联合白蛋白水平,显著优于单用抗体水平或基线评估,等待至6个月无额外获益。

研究设计与样本

  • 研究使用MENTOR试验中85例抗PLA2R抗体≥14 RU/ml的膜性肾病患者队列,识别环孢素或利妥昔单抗治疗12个月后未达蛋白尿缓解的风险因素,考虑基线、治疗3个月和6个月三个landmark时间点,采用逻辑回归模型并用C-statistic和模型拟合(AIC、R²)评估性能。

主要发现

  • 基线最佳预测无缓解模型包括抗PLA2R抗体>323 RU/ml和肌酐清除率。
  • 治疗3个月最佳模型包括抗体和白蛋白相对基线的变化。
  • 治疗6个月最佳模型包括抗体水平>14 RU/ml、肌酐清除率和白蛋白相对基线的变化。
  • 与基线模型相比,3个月模型模型拟合更优(AIC 70.9 vs 96.4,R² 51.8% vs 30.1%)且C-statistic更高(0.93 vs 0.83,P=0.008)。
  • 6个月模型与3个月模型性能无差异(AIC 68.6,R² 53.0%,C-statistic 0.94,P=0.67)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal timing to evaluate antibody levels and how to combine them with other clinical variables are currently unknown. METHODS: We used a cohort of 85 patients from the Membranous Nephropathy Trial Of Rituximab (MENTOR) with anti-PLA2R antibodies ≥14 RU/ml to identify risk factors for not experiencing proteinuria remission after 12 months of treatment with cyclosporine or rituximab. Three landmark times were considered: at baseline and after 3 and 6 months of treatment. Logistic regression model performance was evaluated using C-statistics and model fit (Akaike information criterion [AIC], R 2 ). RESULTS: The model at baseline that best predicted no remission included anti-PLA2R antibodies >323 RU/ml and creatinine clearance; the best model after 3 months included the change from baseline in both antibody and albumin levels; and the best model after 6 months included antibody levels >14 RU/ml, creatinine clearance, and the change from baseline in albumin. Compared with the model at baseline, the model at 3 months had better model fit (AIC 70.9 versus 96.4, R 2 51.8% versus 30.1%) and higher C-statistic (0.93 versus 0.83, P = 0.008). The model at 6 months had no difference in performance compared with the model at 3 months (AIC 68.6, R 2 53.0%, C-statistic 0.94, P = 0.67). CONCLUSIONS: In patients with membranous nephropathy treated with cyclosporine or rituximab in the MENTOR trial, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_10_09_CJN0000000000000237.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Barbour SJ, Fervenza FC, Induruwage D, et al. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy. Clin J Am Soc Nephrol. 2023. PMID: 37471101. doi:10.2215/CJN.0000000000000237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。